An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: Implication for developing anti-HIV microbicides

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2533-2544

  Tong, Pei ^a   Lu, Zhifeng ^a   Chen, Xi ^a   Wang, Qian ^b   Yu, Fei ^c   Zou, Peng ^c   Yu, Xiaoxia ^d   Li, Yu ^a   Lu, Lu ^b,c   Chen, Ying Hua ^a   Jiang, Shibo ^b,c  

^a Tsinghua University   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Disulphide bonds; Enfuvirtide; N heptad repeat; Tenofovir; Trimer

Indexed keywords

ENFUVIRTIDE; GAG PROTEIN; HYDROXYETHYLCELLULOSE; LUCIFERASE; MICROBICIDE; MONOMER; RECOMBINANT PROTEIN; TENOFOVIR; TETRAZOLIUM; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CIRCULAR DICHROISM; CYTOTOXICITY; DIGESTION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PH; POLYMERIZATION; SEDIMENTATION RATE; SEMINAL PLASMA; THERMOSTABILITY; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS TRANSMISSION;

DISULPHIDE BONDS; ENFUVIRTIDE; N-HEPTAD REPEAT; TENOFOVIR; TRIMER;

ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; CIRCULAR DICHROISM; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; ULTRACENTRIFUGATION;

EID: 84886265114     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt230     Document Type: Article

References (57)

1. UNAIDS. AIDS Epidemic Update http://data.unaids.org/pub/report/2009/jc1700_epi_update_2009_en.pdf (3 May, 2013, date last accessed).
2. UNAIDS. Redefining AIDS in Asia.http://data.unaids.org/pub/Report/2008/20080326_report_commission_aids_en.pdf (3 May, 2013, date last accessed).
3. Roehr B. Microbicide offers no protection against HIV infection. Br Med J 2009; 339: b5538.
4. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 2010; 23: 26-31.
5. Bollen LJM, Blanchard K, Kilmarx PH et al. No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial. J Acquir Immune Defic Syndr 2008; 47: 253-7.
6. Perotti ME, Pirovano A, Phillips DM. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol Repro 2003; 69: 933-9.
7. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359: 463-72. Erratum in: N Engl J Med 2008; 359: 877.
8. Check E. Scientists rethink approach to HIV gels. Nature 2007; 446: 12.
9. Keller MJ, Herold BC. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm Dis 2009; 36: S92-S5.
10. ZhuTF,MoHM,WangNet al. Genotypicandphenotypiccharacterization of HIV-1 in patients with primary infection. Science 1993; 261: 1179-81.
11. Royce RA, Sena A, CatesWet al. Current concepts: sexual transmission of HIV. N Engl J Med 1997; 336: 1072-8.
12. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007; 73: 911-22.
13. Rohan LC, Moncla BJ, Ayudhya R et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010; 5: e9310.
14. Das K, Clark AD, Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47: 2550-60.
15. Woolfson AD, Malcolm RK, Morrow RJ et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325: 82-9.
16. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
17. Garg AB, Nuttall J, RomanoJ. The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 2009; 19: 143-50.
18. Wild CT, Shugars DC, Greenwell TK et al. Peptides corresponding to a predicative alpha-helical domain of human-immunodeficiency virus type-1 gp41 are potent inhibitors of virus-infection. Proc Natl Acad Sci USA 1994; 91: 9770-4.
19. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
20. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
21. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438: 99-102.
22. Li L, Ben Y, Yuan S et al. Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. PLoS One 2012; 7: e37381.
23. Harman S, Herrera C, Armanasco N et al. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother 2012; 56: 2347-56.
24. Bird GH, Madani N, Perry AFet al. Hydrocarbon double-stapling remedies the proteolytic instability of alengthy peptide therapeutic. ProcNatl AcadSci USA 2010; 107: 14093-8.
25. Chen X, Lu L, Qi Z et al. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J Biol Chem 2010; 285: 25506-15.
26. Kilby JM, Lalezari JP, Eron JJ et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retrovir 2002; 18: 685-93.
27. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J 2009; 11: 78-87.
28. Hunter CA, Lu XJ. Construction of double-helical DNA structures based on dinucleotide building blocks. J Biomol Struct Dyn 1997; 14: 747-56.
29. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
30. Eckert DM, Malashkevich VN, Hong LH et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-15.
31. Bewley CA, Louis JM, Ghirlando Ret al. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277: 14238-45.
32. Liu SW, Lu H, Niu J et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005; 280: 11259-73.
33. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91-5.
34. Lu L, Tong P, Yu XWet al. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Biochim Biophys Acta-Biomembr 2012; 1818: 2950-7.
35. ShuW, Liu J, Ji H et al. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000; 39: 1634-42.
36. Geuenich S, Goffinet C, Venzke S et al. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology 2008; 5: 27.
37. Wang J, Tong P, Lu L et al. HIV-1 gp41 Core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One 2011; 6: e18233.
38. Wild J, Kamath-Loeb A, Ziegelhoffer E et al. Partial loss of function mutations in DnaK, the Escherichia coli homologue of the 70-kDa heat shock proteins, affect highly conserved amino acids implicated in ATP binding and hydrolysis. Proc Natl Acad Sci USA 1992; 89: 7139-43.
39. Li L, He L, Tan S et al. 3-Hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother 2010; 54: 1700-11.
40. Chatterjee S, JiangW, Emerson SD et al. The backbone structure of the major cold-shock protein CS7.4 of Escherichia coli in solution includes extensive b-sheet structure. J Biochem 1993; 114: 663-9.
41. Li L, Qiao P, Yang J et al. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology 2010; 7: 37.
42. Pan CG, Cai LF, Lu H et al. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J Virol 2009; 83: 7862-72.
43. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug-combination studies. Pharmacol Rev 2006; 58: 621-81. Erratumin: Pharmacol Rev 2007; 59: 124.
44. ZhuY, LuL,XuLet al. Identification ofagp41core-bindingmoleculewith homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor. J Virol 2010; 84: 9359-68.
45. Fernandez-Romero JA, Thorn M, Turville SG et al. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34: 9-14.
46. Fletcher PS, Harman SJ, Boothe AR et al. Preclinical evaluation of lime juice as a topical microbicide candidate. Retrovirology 2008; 5: 3.
47. Louis JM, Bewley CA, Clore GM. Design and properties of N-CCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001; 276: 29485-9.
48. Habazettl J, Reiner A, Kiefhaber T. NMR Structure of a monomeric intermediate on the evolutionarily optimized assembly pathway of a small trimerization domain. J Mol Biol 2009; 389: 103-14.
49. Lelj-Garolla B, Mauk AG. Self-association and chaperone activity of Hsp27 are thermally activated. J Biol Chem 2006; 281: 8169-74.
50. Papanikolopoulou K, Forge V, Goeltz P et al. Formation of highly stable chimeric trimers by fusion of an adenovirus fiber shaft fragment with the foldon domain of bacteriophage T4 fibritin. J Biol Chem 2004; 279: 8991-8.
51. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptide. J Virol 1998; 72: 986-93.
52. Sigal A, KimJT, BalazsABet al.Cell-to-cell spreadof HIVpermits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.
53. Neurath AR, Strick N, Li YY. Role of seminal plasma in the anti-HIV-activity of candidate microbicides. BMC Infect Dis 2006; 6: 150.
54. Hillier SL, Moench T, Shattock R et al. In vitro and in vivo: the story of Nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8.
55. Nel AM, Coplan P, van de Wijgert JH et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23: 1531-8.
56. Veazey RS, Ketas TJ, Dufour J et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202: 739-44.
57. Tsibris AM, Pal U, Schure AL et al. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One 2011; 6: e28047.